Metabolomics in neuroscience and disease

Global Metabolic Profiling: Clinical Applications

Volumn , Issue , 2014, Pages 162-180

  Rae, Caroline ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METABOLOMICS; SAMPLE COLLECTION;

EID: 84911873259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4155/EBO.13.483     Document Type: Chapter

References (39)

1. Menken M, Munsat TL, Toole JF. The global burden of disease study - implications for neurology. Arch. Neurol. 57(3), 418-420 (2000).
2. Daviss B. Growing pains for metabolomics. The Scientist 19, 25-28 (2005).
3. Kaddurah-Daouk R, Krishnan KRR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychpharmacology 34(1), 173-186 (2009).
4. Gebregiworgis T, Powers R. Application of NMR metabolomics to search for human disease biomarkers. Comb. Chem. High Throughput Screen. 15(8), 595-610 (2012).
5. Hassan-Smith G, Wallace GR, Douglas MR, Sinclair AJ. The role of metabolomics in neurological disease. J. Neuroimmunol. 248(1-2), 48-52 (2012).
6. Maher AD, Solo V, Rae CD. Magneti resonance-based metabolomics for understanding neurological disorders: current status and considerations. Curr. Metab. 1(1) (2013) (In Press).
7. Wishart DS, Jewison T, Guo AC et al. HMDB 3.0 - the Human Metabolome Database in 2013. Nucleic Acids Res. 41(D1), D801-D807 (2013).
8. Mandal R, Guo AC, Chaudhary KK et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med. 4(4), 38 (2012).
9. Burnham SC, Faux NG, Wilson W et al. A blood-based predictor for neocortical Ab burden in Alzheimer's disease: results from the AIBL study. Mol. Psychiatry doi:2010.1038/mp.2013.2040 (2013) (Epub ahead of print).
10. Penet MF, Kober F, Confort- Gouny S et al. Magneti resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA. J. Biol. Chem. 282(19), 14505-14514 (2007).
11. Caine S, Heraud P, Tobin MJ, McNaughton D, Bernard CC. The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue. Neuroimage 59(4), 3624-3640 (2012).
12. American College of Radiology. ACR-ASNR-SPR Practice Guideline for the Performance and Interpretation of Magnetic Resonance Spectroscopy of the Central Nervous System. American College of Radiology, VA, USA (2013).
13. Lindon JC, Nicholson JK, Holmes E et al. Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol. 23(7), 833-838 (2005).
14. Griffin JL, Steinbeck C. So what have data standards ever done for us? The view from metabolomics. Genome Med. 2(6), 38 (2010).
15. Crews B, Wikoff WR, Patti GJ et al. Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data. Anal. Chem. 81(20), 8538-8544 (2009).
16. Button KS, Ioannidis JP, Mokrusz C et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14(5), 365-376 (2013).
17. Zucchini W. An introduction to model selection. J. Math. Psychol. 44(1), 41-61 (2000).
18. Hall P, Marron JS, Neeman A. Geometric representation of high dimension, low sample size data. J. R. Stat. Soc. Ser. B 67, 427-444 (2005).
19. Jung S, Marron JS. PCA consistency in high dimension, low sample size context. Ann. Stat. 37(6B), 4104-4130 (2009).
20. Go EP. Database resources in metabolomics: an overview. Neuroimmune Pharmacol. 5(1), 18-30 (2010).
21. Maher AD, Cysique LA, Brew BJ, Rae CD. Statistical integration of H-1 NMR and MRS data from different biofl ids and tissues enhances recovery of biological information from individuals with HIV-1 infection. Proteome Res. 10(4), 1737-1745 (2011).
22. Tisell A, Dahlqvist LO, Warntjes J, Lundberg P. Procedure for quantitative 1H MRS and tissue characterization of human brain tissue based on the use of quantitative MRI. Magn. Reson. Med. doi:10.1002/ mrm.24554 (2013) (Epub ahead of print).
23. Cocuzzo D, Lin A, Ramadan S, Mountford C, Keshava N. Algorithms for characterizing brain metabolites in two-dimensional in vivo MR correlation spectroscopy. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 4929-4934 (2011).
24. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2(4), 171-196 (2006).
25. Stanwell P, Siddall P, Keshava N et al. Neuro magnetic resonance spectroscopy using wavelet decomposition and statistical testing identifies biochemical changes in people with spinal cord injury and pain. Neuroimage 53(2), 544-552 (2010).
26. Szymanska E, Saccenti E, Smilde AK, Westerhuis JA. Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics 8(Suppl. 1), S3-S16 (2012).
27. Rae C, Henry RG. Mind meld: collaborative approaches to understanding how we all think. Brain Imaging Behav. 2(4), 343-349 (2008).
28. He Y, Yu Z, Giegling I et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl. Psychiatry 2, e149 (2012).
29. Pickard B. Progress in defining the biological causes of schizophrenia. Expert Rev. Mol. Med. 13, e25 (2011).
30. Holmes E, Tsang TM, Huang JTJ et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), 1420 (2006).
31. Smesny S, Rosburg T, Nenadic I et al. Metabolic mapping using 2D (31)P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage 35(2), 729-737 (2007).
32. Martinez-Granados B, Brotons O, Martinez-Bisbal MC et al. Spectroscopic metabolomic abnormalities in the thalamus related to auditory hallucinations in patients with schizophrenia. Schizophr. Res. 104(1-3), 13-22 (2008).
33. Kaddurah-Daouk R, McEvoy J, Baillie RA et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12(10), 934-945 (2007).
34. Xuan JK, Pan GH, Qiu YP et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J. Proteome Res. 10(12), 5433-5443 (2011).
35. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural types. J. Neurosci. 13, 981-989 (1993).
36. Allen GI, Maletic-Savatic M. Sparse non-negative generalized PCA with applications to metabolomics. Bioinformati s 27(21), 3029-3035 (2011).
37. Nasrallah FA, Maher AD, Hanrahan JR, Balcar VJ, Rae CD. g-hydroxybutyrate and the GABAergic footprint. A metabolomic approach to unpicking the actions of HB. J. Neurochem. 115, 58-67 (2010).
38. Absalom N, Eghorn LF, Villumsen IS et al. alpha 4 beta delta GABA(A) receptors are high-affinity targets for gamma-hydroxybutyric acid (GHB). Proc. Natl Acad. Sci. USA 109(33), 13404-13409 (2012).
39. Qiao HY, Zhang XL, Zhu XH, Du F, Chen W. In vivo P-31 MRS of human brain at high/ultrahigh fields: a quantitative comparison of NMR detection sensitivity and spectral resolution between 4 T and 7 T. Magn. Reson. Imaging 24(10), 1281-1286 (2006).